Literature DB >> 27694858

Reply to Kim J.S. and Kim B.-W.

Jyh-Ming Liou1, Chi-Yang Chang2, Ming-Shiang Wu1.   

Abstract

Year:  2016        PMID： 27694858     DOI： 10.1038/ajg.2016.311

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  6 in total

1.  Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial.

Authors:  Jyh-Ming Liou; Chieh-Chang Chen; Mei-Jyh Chen; Chi-Yang Chang; Yu-Jen Fang; Ji-Yuh Lee; Wang-Huei Sheng; Hsiu-Po Wang; Ming-Shiang Wu; Jaw-Town Lin
Journal:  J Antimicrob Chemother       Date:  2011-05-31       Impact factor: 5.790

2.  Levofloxacin-Containing Sequential Therapy May Not Be Better than Levofloxacin Triple Therapy after Failure of Non-Bismuth Quadruple Therapies.

Authors:  Joon Sung Kim; Byung-Wook Kim
Journal:  Am J Gastroenterol       Date:  2016-10       Impact factor: 10.864

3.  Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection.

Authors:  Alessandro Federico; Gerardo Nardone; Antonietta G Gravina; Maria Rosaria Iovene; Agnese Miranda; Debora Compare; Paola A Pilloni; Alba Rocco; Luigi Ricciardiello; Riccardo Marmo; Carmelina Loguercio; Marco Romano
Journal:  Gastroenterology       Date:  2012-04-03       Impact factor: 22.682

4.  Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial.

Authors:  Jyh-Ming Liou; Chieh-Chang Chen; Chi-Yang Chang; Mei-Jyh Chen; Yu-Jen Fang; Ji-Yuh Lee; Chien-Chuan Chen; Shih-Jer Hsu; Yao-Chun Hsu; Cheng-Hao Tseng; Ping-Huei Tseng; Lawrence Chang; Wen-Hsiung Chang; Hsiu-Po Wang; Chia-Tung Shun; Jeng-Yih Wu; Yi-Chia Lee; Jaw-Town Lin; Ming-Shiang Wu
Journal:  J Antimicrob Chemother       Date:  2012-10-25       Impact factor: 5.790

5.  Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.

Authors:  Jyh-Ming Liou; Chieh-Chang Chen; Mei-Jyh Chen; Chien-Chuan Chen; Chi-Yang Chang; Yu-Jen Fang; Ji-Yuh Lee; Shih-Jer Hsu; Jiing-Chyuan Luo; Wen-Hsiung Chang; Yao-Chun Hsu; Cheng-Hao Tseng; Ping-Huei Tseng; Hsiu-Po Wang; Ueng-Cheng Yang; Chia-Tung Shun; Jaw-Town Lin; Yi-Chia Lee; Ming-Shiang Wu
Journal:  Lancet       Date:  2012-11-16       Impact factor: 79.321

6.  Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori: A Randomized Trial.

Authors:  Jyh-Ming Liou; Ming-Jong Bair; Chieh-Chang Chen; Yi-Chia Lee; Mei-Jyh Chen; Chien-Chuan Chen; Cheng-Hao Tseng; Yu-Jen Fang; Ji-Yuh Lee; Tsung-Hua Yang; Jiing-Chyuan Luo; Jeng-Yih Wu; Wen-Hsiung Chang; Chun-Chao Chang; Chi-Yi Chen; Po-Yueh Chen; Chia-Tung Shun; Wen-Feng Hsu; Hsu-Wei Hung; Jaw-Town Lin; Chi-Yang Chang; Ming-Shiang Wu
Journal:  Am J Gastroenterol       Date:  2016-02-02       Impact factor: 10.864
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.